United States: Combination Products: Regulatory And Patent Issues You Should Consider Now

Products involving combinations of drugs, biological products, and medical devices are becoming increasingly prominent. Combination products can involve components that are physically, chemically, or otherwise combined (e.g., a monoclonal antibody with a therapeutic drug); components that are packaged together (e.g., a drug packaged with a delivery device); or components that are provided separately but intended to be used together (e.g., a photosensitizing drug and activating light source).1

Combination products can follow a variety of regulatory pathways, each with its own benefits and shortcomings. FDA notes that a product's pathway "can impact the regulatory processes for all aspects of product development and management, including preclinical testing, clinical investigation, marketing applications, manufacturing and quality control, adverse event reporting, promotion and advertising, and post-approval modifications."2 The most successful companies begin targeting a regulatory pathway from the earliest stages of development, based at least in part on the regulatory and patent considerations discussed in this article.

REGULATORY PATHWAYS FOR COMBINATION PRODUCTS

A combination product's regulatory pathway generally depends on its primary mode of action (PMOA), recently defined in the 21st Century Cures Act as "the single mode of action of a combination product expected to make the greatest contribution to the overall intended therapeutic effects of the combination product."3,4 FDA's Office of Combination Products (OCP) examines the product's modes of action, determines which is the PMOA, and then uses that to assign the product to a particular FDA center for premarket review and regulation.5

Classification is more complicated if the PMOA is not clearly identified or there are two independent, equally important modes of action. In these cases, OCP generally looks to the product's most critical safety and efficacy issues, classifying the product either in accordance with other products raising the same issues or based on which FDA center is most experienced with such issues.6

Drug-Lead Products

If a combination product is classified as a drug lead, OCP assigns it to FDA's Center for Drug Evaluation and Research (CDER) for premarket review and regulation.7 Companies with an innovative drug-lead product generally must file a new drug application (NDA), which can cost up to $2.4 million in FDA application fees alone and take one year or more for FDA review.8, 9 This is in addition to the years and millions of dollars spent in development before the NDA is even filed.10

Combination products approved under an NDA may be eligible to receive five years or more of exclusivity from FDA.11 But the primary advantage of having a drug lead in a combination product can be summarized in three words: the Orange Book. The FDA Orange Book lists drug-lead products, along with patents covering the products, their active ingredients, and methods of use.12, 13 Companies benefit from these listings, because they provide notice of the patents to the public and give rise to the patent-related protections of the Hatch-Waxman Act.14

Under Hatch-Waxman, an NDA holder can sue a company seeking to market a generic version of its drug-lead product before it otherwise might be able to. More specifically, a company seeking to market a generic version of a drug can avoid the lengthy and costly NDA process by filing an abbreviated new drug application (ANDA), which relies on the data reported in the NDA.15 An ANDA filer must certify that each patent listed in the Orange Book either will expire before the generic product goes on the market (paragraph III certification), or is invalid, unenforceable, or will not be infringed by the product (paragraph IV certification).16 If the ANDA filer makes a paragraph IV certification, the NDA holder can sue for patent infringement before the proposed generic product is made, used, or sold. In addition, paragraph IV suits trigger a stay where FDA cannot approve the generic product application for up to 30 months.17, 18

Biological-Lead Products

If a combination product is classified as a biological-product lead, it is not eligible for listing in the Orange Book, and OCP will assign it to FDA's Center for Biologics Evaluation and Research (CBER) for premarket review and regulation.19 Companies with an innovative biological-lead product generally must file a biologic license application (BLA), which can cost more than $260,000 in FDA application fees alone and take one year or more for FDA review.9, 20 This is in addition to the years and millions of dollars spent in development before the BLA is even filed.21

Combination products approved under a BLA may be eligible for 12 years or more of FDA exclusivity.22 FDA lists the products and some of their exclusivities in its Purple Book publication.23 Unlike the Orange Book for drug-lead products, the Purple Book does not include patents. BLAs instead implicate the patent protections of the Biologics Price Competition and Innovation Act (BPCIA).24

Under BPCIA, a BLA holder can sue a company seeking to market a generic version of its biological-lead product before it otherwise might be able to. Similar to drug-lead products, a company seeking to market a generic version of a biological-lead product might be able to avoid part of the time and cost associated with filing a BLA by filing an abbreviated application that relies on the BLA holder's data.25 This filing may trigger a "patent dance" whereby the applicant and BLA holder exchange information and arrive at a list of patents subject to a patent-infringement action.26 Unlike with Hatch-Waxman litigation for drug-lead products, BPCIA patent litigation does not trigger a regulatory stay of approval for the generic product.

Medical-Device Lead Products

If a combination product is classified as a medical-device lead, it is not eligible for listing in the Orange Book or the Purple Book, and OCP will assign it to FDA's Center for Devices and Radiological Health (CDRH) for premarket review and regulation.27 Companies with an innovative medical-device-lead product generally must file a premarket approval application (PMA), which can cost more than $260,000 in FDA application fees alone and take about one year for FDA review.9, 20 Although this is in addition to the time and money spent in development,28 such time and cost are generally less than with drug-lead and biological-lead products. In addition, if the product contains only a small change over a previously approved device, the company can reduce time and cost even further by filing a premarket notification (PMN) instead of a PMA.

Combination products with medical-device leads do not receive FDA exclusivities, and their only patent-related protection is the patent term itself. As such, a company might need to wait until the medical-device-lead product is made, used, or sold before suing for patent infringement. Medical-device-lead products are generally listed in the FDA Global Unique Device Identification Database (GUDID), which does not include patent information, although one of the database's goals is better detection of counterfeit devices.29

PURSUING A PARTICULAR REGULATORY PATHWAY

Companies should decide which regulatory pathway to pursue early on, based on their time and cost goals and their patent portfolios. While development and approval for drug-lead and biological-product-lead combination products is lengthy and expensive, pursuing them may come with FDA data exclusivities and patent-related protections, as discussed above, that make the time and cost worthwhile. Pursuing a drug lead or biological-product lead is more likely a strong choice if the combination product enjoys a robust patent portfolio. On the other hand, if the product does not have a robust patent portfolio, or a more timely approval at a lower cost is the goal, pursuing the medical-device-lead pathway might be the best strategy.

Once a company decides which pathway will likely be most beneficial for its product, it should take steps to ensure that OCP assigns the product to that pathway. The most obvious way to do this is to ensure that the product's PMOA corresponds to the desired lead. To the extent that a product's PMOA is unclear, a company can ask OCP to assign the product to its preferred pathway in a Request for Designation (RFD). A company might be able to influence OCP's decision about product lead by consistently characterizing the product's therapeutic effect as attributed to the preferred lead, by analogizing the product to other products that OCP previously assigned to that lead, or by emphasizing safety and effectiveness issues that call for the expertise of the preferred center. For example, if a company consistently emphasizes the product's drug component during patent prosecution as providing the most important therapeutic action, OCP might be influenced to assign the product to CDER. Under the recent 21st Century Cures Act, FDA now must provide a substantive rationale when it disagrees with a company's determination of a combination product's PMOA.30

The choice of regulatory pathway must be balanced against the ability to obtain and leverage a robust patent portfolio. The ability to obtain a robust portfolio might depend on whether the company disclosed the product or its therapeutic action before it filed the patent application with the US Patent and Trademark Office (USPTO). For example, statements about a product at a trade show or in a peer-reviewed publication might preclude a company from securing a patent for the product. The ability to leverage a robust patent portfolio might depend on whether the company made statements to FDA that contradict statements in the patents or made to the USPTO during prosecution. For example, companies should take care in making statements when seeking authorization for human testing of a drug-lead product, submitting proposed labels to FDA for biological-lead products, or seeking approval for a new medical-device-lead product that relies on a predicate device. Companies developing combination products should strive for open communication and strategic coordination among scientists, individuals tasked with preparing FDA submissions, and individuals tasked with obtaining and leveraging the company's patents.

CONCLUSION

Although combination products raise challenges for FDA and companies alike, they also can provide opportunities for companies that strategize from the earliest stages to pursue the most beneficial regulatory pathway for their products. In developing a combination-product strategy, companies should consider regulatory and patent issues, including how these issues might be affected by ever-changing laws and regulations.

Originally printed in  Pharmaceutical Technology on February 23, 2017.

Footnotes

1 FDA, Frequently Asked Questions About Combination Products (Oct. 20, 2016) (citing Code of Federal Regulations, Title 21, Section 3.2(e)), accessed Feb. 6, 2017.

2 FDA, About Combination Products (Sept. 8, 2016), accessed Feb. 6, 2017.

3 21st Century Cures Act of 2016, Pub. L. No. 114-255, § 3038 (amending United States Code, Title 21, Section 353(g)).

4 Code of Federal Regulations, Title 21, Section 3.2(m).

5 Code of Federal Regulations, Title 21, Section 3.4.

6 Code of Federal Regulations, Title 21, Section 3.4(b).

7 Code of Federal Regulations, Title 21, Section 3.4(a)(1).

8 FDA, Prescription Drug User Fee Rates for Fiscal Year 2016, Fed. Reg. 80 (148), 46028–46031 (Aug. 3, 2015).

9 FDA, FY2015 Performance Report to Congress for the Office of Combination Products 14-15 (2016), accessed Feb. 6, 2017.

10 J. A. DiMasi et al., J. Health Econ. 47 (20) (2016).

11 Code of Federal Regulations, Title 21, Section 314.108.

12 Code of Federal Regulations, Title 21, Section 314.53(b).

13 FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, accessed Feb. 6, 2017.

14 Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (amending United States Code, Title 21, Section 355).

15 United States Code, Title 21, Section 355(j).

16 United States Code, Title 21, Section 355(j)(2)(A).

17 United States Code, Title 21, Section 355(j)(5)(B)(iii).

18 United States Code, Title 21, Section 355(c)(3)(E)(ii) (providing that the thirty-month period is extended in certain circumstances).

19 Code of Federal Regulations, Title 21, Section 3.4(a)(3).

20 FDA, Medical Device User Fee Rates for Fiscal Year 2016, Fed. Reg. 80 (148), 46033–46035 (Aug. 3, 2015).

21 J. A. DiMasi and H. G. Grabowski, Manage. Decis. Econ. 28 (469) (2007).

22 United States Code, Title 42, Section 262(k)(7)(A).

23 FDA, Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations.

24 Biologics Price Competition and Innovation Act of 2009, in the Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119, 804-21 (2010) (amending United States Code, Title 42, Section 262).

25 United States Code, Title 42, Section 262(k).

26 United States Code, Title 42, Section 262(l).

27 Code of Federal Regulations, Title 21, Section 3.4(a)(2).

28 Josh Makower, et al., FDA Impact on US Medical Technology Innovation (November 2010), accessed Feb. 6, 2017.

29 FDA, Unique Device Identification System, Fed. Reg. 78 (185), 58786–58787 (Sept. 24, 2013).

30 21st Century Cures Act of 2016, Pub. L. No. 114-255 § 3038(a)(4) (amending United States Code, Title 21, Section 353(g)).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
24 Jul 2018, Webinar, Washington, DC, United States

The program will consider arguments that have worked to avoid a finding of inequitable conduct or unclean hands and those that have not been successful.

9 Aug 2018, Webinar, Washington, DC, United States

As part of Strafford Publications’ webinar series, Finnegan partners Shana Cyr and Barbara Rudolph will discuss best practices for patent counsel navigating the 30-month stay in Hatch-Waxman Act litigation.

5 Sep 2018, Webinar, Washington, DC, United States

Finnegan’s 2018 webinar series addresses challenges across the IP landscape in the United States. The series starts with one of the fundamentals—proving or disproving obviousness. The panelists will address what works and what doesn’t before U.S. Patent and Trademark Office (USPTO) examiners, before the Patent Trial and Appeal Board (PTAB), and before the courts.

 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions